Objective To summarize the 2010 EFNS/MDS‐ES evidence‐based treatment
recommendations for the management of P arkinson's disease (PD). This summary includes …

Affective disorders, cognitive decline, and psychosis have long been recognized as common
in Parkinson disease (PD), and other psychiatric disorders include impulse control …

The objective of investigation was to prepare nanoemulsion containing risperidone (RSP) to
accomplish the delivery of drug to the brain via nose. Risperidone nanoemulsion (RNE) and …

To provide evidence‐based recommendations for the management of late (complicated)
Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to …

Psychotic symptoms in Parkinson's disease (PD) are relatively common and, in addition to
creating a disturbance in patients' daily lives, have consistently been shown to be …

The objective of the present study was to optimize olanzapine nanoemulsion (ONE), for
nose-to-brain delivery. The nanoemulsions and olanzapine mucoadhesive nanoemulsions …

Background In many countries of the industrialised world second‐generation (" atypical")
antipsychotics (SGAs) have become the first line drug treatment for people with …

Psychotic symptoms are a frequent occurrence in Parkinson's disease (PD), affecting up to
50% of patients. The Movement Disorder Society established a Task Force on Rating Scales …

Background: Although the diagnosis of Parkinson disease (PD) still relies mainly on the
appearance of its classical motor features of resting tremor, rigidity, bradykinesia, and …

Psychotic symptoms are common in Parkinson's disease (PD), generally associated with the
medications used to treat the motor symptoms. On rare occasion they occur in patients not …